New device could help patients with Hard-to-Control blood pressure

NCT ID NCT07081243

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 500 people in China with resistant hypertension who have already received the Symplicity Spyral renal denervation system. The device uses radiofrequency energy to calm overactive kidney nerves that can raise blood pressure. Researchers will track blood pressure changes, medication use, and safety for up to 36 months to see if the treatment provides lasting benefits.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Symplicity Spyral Renal Denervation System (a device that uses radiofrequency energy to disrupt nerves in the kidney arteries to lower blood pressure)
What this could lead to
If successful, this could confirm that renal denervation provides lasting blood pressure reduction for people with resistant hypertension, offering an alternative to lifelong medication.
What could go wrong
This is an observational study, not a randomized trial, so results may be less definitive. The device is already approved, but long-term durability and safety in a real-world Chinese population are still being assessed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESISTANT HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Zhongshan Hospital Fudan University

    RECRUITING

    Shanghai, Shanghai Municipality, 210000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.